Among patients with PLA2R1-associated membranous nephropathy, 10 patients (83%) in the obinutuzumab or ofatumumab group and 7 patients (47%) in the rituximab group achieved immunological remission at month 12 (P = 0.1) (Table 2). This evidence concerns the gene PLA2R1 and membranous glomerulonephritis.